Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
August 31, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 10, 2023 07:00 ET
|
Larimar Therapeutics
Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension...
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
July 25, 2023 07:00 ET
|
Larimar Therapeutics
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing...
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
July 17, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Set to Join Russell 3000® Index
June 21, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
May 15, 2023 07:00 ET
|
Larimar Therapeutics
Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28Daily...
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
March 28, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
March 14, 2023 07:00 ET
|
Larimar Therapeutics
First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as plannedLarimar expects to provide an update on...
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
February 07, 2023 16:05 ET
|
Larimar Therapeutics
Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar’s clinical and R&D programs BALA CYNWYD, Pa., Feb. 07, 2023 (GLOBE...
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
November 21, 2022 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...